KIT and acute myeloid leukemia: These data show that six markers (i.e, CD34, CD117, CD13, CD33, MPO, and HLA-DR) used to diagnose AML in routine clinical practice are differentially expressed in six immunophenotypically defined stages of normal myelopoiesis.